References
- Althof, S., Derogatis, L. R., Greenberg, S., Clayton, A. H., Jordan, R., Lucas, J., & Spana, C. (2019). Responder analyses from a phase 2b dose-ranging study of bremelanotide. The Journal of Sexual Medicine, 16(8), 1226–1235. https://doi.org/https://doi.org/10.1016/j.jsxm.2019.05.012
- Altman, D. G., & Royston, P. (2006). The cost of dichotomising continuous variables. BMJ, 332(7549), 1080. https://doi.org/https://doi.org/10.1136/bmj.332.7549.1080
- AMAG Pharmaceuticals. (2020, July 27). AMAG pharmaceuticals completes divestment of women’s health assets – AMAG pharmaceuticals. AMAG Pharmaceuticals. https://www.amagpharma.com/news/amag-pharmaceuticals-completes-divestment-of-womens-health-assets/
- American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.).
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
- Angelmar, R., Angelmar, S., & Kane, S. (2007). Building strong condition brands. Journal of Medical Marketing, 7(4), 341–351. https://doi.org/https://doi.org/10.1057/palgrave.jmm.5050101
- Armstrong, D. (2006). Medical reviews face criticism over lapses. Wall Street Journal, p. B1.
- Battisti, W. P., Wager, E., Baltzer, L., Bridges, D., Cairns, A., Carswell, C. I., Citrome, L., Gurr, J. A., Mooney, L. A., Moore, B. J., Peña, T., Sanes-Miller, C. H., Veitch, K., Woolley, K. L., & Yarker, Y. E. (2015). Good publication practice for communicating company-sponsored medical research: GPP3. Annals of Internal Medicine, 163(6), 461–464. https://doi.org/https://doi.org/10.7326/M15-0288
- Biostat. (2010). Comprehensive meta-analysis. Biostat.
- Border, R., Johnson, E. C., Evans, L. M., Smolen, A., Berley, N., Sullivan, P. F., & Keller, M. C. (2019). No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. American Journal of Psychiatry, 176(5), 376–387. https://doi.org/https://doi.org/10.1176/appi.ajp.2018.18070881
- Bradley, H. A., Rucklidge, J. J., & Mulder, R. T. (2017). A systematic review of trial registration and selective outcome reporting in psychotherapy randomized controlled trials. Acta Psychiatrica Scandinavica, 135(1), 65–77. https://doi.org/https://doi.org/10.1111/acps.12647
- Brotto, L. A. (2010). The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior, 39(2), 221–239. https://doi.org/https://doi.org/10.1007/s10508-009-9543-1
- Camerer, C. F., Dreber, A., Forsell, E., Ho, T.-H., Huber, J., Johannesson, M., Kirchler, M., Almenberg, J., Altmejd, A., Chan, T., Heikensten, E., Holzmeister, F., Imai, T., Isaksson, S., Nave, G., Pfeiffer, T., Razen, M., & Wu, H. (2016). Evaluating replicability of laboratory experiments in economics. Science, 351(6280), 1433–1436. https://doi.org/https://doi.org/10.1126/science.aaf0918
- Cates, C. J. (n.d.). Visual RX, Version 3. Cates, C. nntonline.net/visualrx
- Chan, A. W., Hrobjartsson, A., Haahr, M. T., Gotzsche, P. C., & Altman, D. G. (2004). Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. The Journal of the American Medical Association, 291(20), 2457–2465. https://doi.org/https://doi.org/10.1001/jama.291.20.2457
- Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., Kaminetsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325–337. https://doi.org/https://doi.org/10.2217/whe-2016-0018
- Clayton, A. H., Segraves, R. T., & Pyke, R. E. (2018). A brief version of the Sexual Interest and Desire Inventory–Female with 4 core items. The Journal of Sexual Medicine, 15(9), 1370–1371. https://doi.org/https://doi.org/10.1016/j.jsxm.2018.07.007
- ClinicalTrials.gov. (2018a, October 2). A phase 3, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02333071
- ClinicalTrials.gov. (2018b, October 2). A phase 3, randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02338960
- CONSORT. (2020). Endorsers: CONSORT transparent reporting of trials. Consolidated Standards of Reporting Trials Group. http://www.consort-statement.org/about-consort/endorsers
- Cosgrove, L., Morrill, Z., Yusif, M., Vaswani, A., Cathcart, S., Troeger, R., & Karter, J. M. (2020). Drivers of and solutions for the overuse of antidepressant medication in pediatric populations. Frontiers in Psychiatry, 11(11), 17. https://doi.org/https://doi.org/10.3389/fpsyt.2020.00017
- Deeks, J. J. (2002). Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine, 21(11), 1575–1600. https://doi.org/https://doi.org/10.1002/sim.1188
- DeRogatis, L., Clayton, A., Lewis-D’Agostino, D., Wunderlich, G., & Fu, Y. (2008). Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. The Journal of Sexual Medicine, 5(2), 357–364. https://doi.org/https://doi.org/10.1111/j.1743-6109.2007.00672.x
- DeRogatis, L., Pyke, R., McCormack, J., Hunter, A., & Harding, G. (2011). Does the Female Sexual Distress Scale-Revised cover the feelings of women with HSDD? The Journal of Sexual Medicine, 8(10), 2810–2815. https://doi.org/https://doi.org/10.1111/j.1743-6109.2011.02385.x
- Derogatis, L. R., Revicki, D. A., & Clayton, A. H. (2020). Instruments for screening, diagnosis, and management of patients with generalized acquired hypoactive sexual desire disorder. Journal of Women’s Health, 29(6), 806–814. https://doi.org/https://doi.org/10.1089/jwh.2019.7917
- DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. https://doi.org/https://doi.org/10.1016/0197-2456(86)90046-2
- Duncan, L. E., & Keller, M. C. (2011). A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. American Journal of Psychiatry, 168(10), 1041–1049. https://doi.org/https://doi.org/10.1176/appi.ajp.2011.11020191
- Fava, G. A. (2016). The hidden costs of financial conflicts of interest in medicine. Psychotherapy and Psychosomatics, 85(2), 65–70. https://doi.org/https://doi.org/10.1159/000442694
- Ferguson, D. M. (2002). Clinical trial development in female sexual dysfunction. Journal of Sex & Marital Therapy, 28(sup1), 77–83. https://doi.org/https://doi.org/10.1080/00926230252851212
- Flake, J. K., & Fried, E. I. (in press). Measurement shmeasurement: Questionable measurement practices and how to avoid them. Advances in Methods and Practices in Psychological Science. https://doi.org/https://doi.org/10.1177/2515245920952393
- Food and Drug Administration. (2014). Scientific workshop on female sexual interest/arousal disorder. United States Food and Drug Administration. https://www.fda.gov/media/130003/download
- Frances, A. (2014). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. William Morrow Paperbacks.
- Fugh-Berman, A. J. (2010). The haunting of medical journals: How Ghostwriting Sold “HRT.” PLoS Medicine, 7(9), e1000335. https://doi.org/https://doi.org/10.1371/journal.pmed.1000335
- Gellad, W. F., Flynn, K. E., & Alexander, G. C. (2015). Evaluation of flibanserin: Science and advocacy at the FDA. Journal of the American Medical Association, 314(9), 869–870. https://doi.org/https://doi.org/10.1001/jama.2015.8405
- Goldstein, S. W. (2009). My turn … Finally. Journal of Sexual Medicine, 6(2), 301–302. https://doi.org/https://doi.org/10.1111/j.1743-6109.2008.01147.x
- Graham, C. A., Boynton, P. M., & Gould, K. (2017). Women’s sexual desire: Challenging narratives of “dysfunction.”. European Psychologist, 22(1), 27–38. https://doi.org/https://doi.org/10.1027/1016-9040/a000282
- Graham, C. A., Brotto, L. A., & Zucker, K. J. (2014). Response to Balon and Clayton (2014): Female sexual interest/arousal disorder is a diagnosis more on firm ground than thin air. Archives of Sexual Behavior, 43(7), 1231–1234. https://doi.org/https://doi.org/10.1007/s10508-013-0248-0
- Hart, B., Lundh, A., & Bero, L. (2012). Effect of reporting bias on meta-analyses of drug trials: Reanalysis of meta-analyses. BMJ, 344(jan03 1), d7202. https://doi.org/https://doi.org/10.1136/bmj.d7202
- Healy, D. (2006). The latest mania: Selling bipolar disorder. PLoS Medicine, 3(4), e185. https://doi.org/https://doi.org/10.1371/journal.pmed.0030185
- Healy, D., & Cattell, D. (2003). Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 183(1), 22–27. https://doi.org/https://doi.org/10.1192/bjp.183.1.22
- Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. Academic Press.
- Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ (British Medical Journal), 327(7414), 557–560. https://doi.org/https://doi.org/10.1136/bmj.327.7414.557
- Hogenmiller, A., Aless, H., & Fugh-Berman, A. (2017, June 14). The score is even. The Hastings Center. Retrieved from The Hastings Center website: https://www.thehastingscenter.org/the-score-is-even/
- Horwitz, A. V., & Wakefield, J. C. (2007). The loss of sadness: How psychiatry transformed normal sorrow into depressive disorder. Oxford University Press.
- Hughes, S., Cohen, D., & Jaggi, R. (2014). Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: A cross-sectional study. BMJ Open, 4(7), e005535. https://doi.org/https://doi.org/10.1136/bmjopen-2014-005535
- Hyman, S. E. (2010). The diagnosis of mental disorders: The problem of reification. Annual Review of Clinical Psychology, 6(1), 155–179. https://doi.org/https://doi.org/10.1146/annurev.clinpsy.3.022806.091532
- Jaspers, L., Feys, F., Bramer, W. M., Franco, O. H., Leusink, P., & Laan, E. T. M. (2016). Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis. JAMA Internal Medicine, 176(4), 453. https://doi.org/https://doi.org/10.1001/jamainternmed.2015.8565
- John, L. K., Loewenstein, G., & Prelec, D. (2012). Measuring the prevalence of questionable research practices with incentives for truth telling. Psychological Science, 23(5), 524–532. https://doi.org/https://doi.org/10.1177/0956797611430953
- Jureidini, J. N., Amsterdam, J. D., & McHenry, L. B. (2016). The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance. The International Journal of Risk & Safety in Medicine, 28(1), 33–43. https://doi.org/https://doi.org/10.3233/JRS-160671
- Jureidini, J. N., & McHenry, L. B. (2020). The illusion of evidence-based medicine: Exposing the crisis of credibility in clinical research. Wakefield Press.
- Jureidini, J. N., McHenry, L. B., & Mansfield, P. R. (2008). Clinical trials and drug promotion: Selective reporting of study 329. International Journal of Risk & Safety in Medicine, 20(1–2), 73–81. https://doi.org/https://doi.org/10.3233/JRS-2008-0426
- Jutel, A. (2010). Framing disease: The example of female hypoactive sexual desire disorder. Social Science & Medicine, 70(7), 1084–1090. https://doi.org/https://doi.org/10.1016/j.socscimed.2009.11.040
- Kaplan, R. M., Irvin, V. L., & Garattini, S. (2015). Likelihood of null effects of large NHLBI clinical trials has increased over time. Plos One, 10(8), e0132382. https://doi.org/https://doi.org/10.1371/journal.pone.0132382
- Kerr, N. L. (1998). HARKing: Hypothesizing after the results are known. Personality and Social Psychology Review, 2(3), 196–217. https://doi.org/https://doi.org/10.1207/s15327957pspr0203_4
- Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics and Gynecology, 134(5), 899–908. https://doi.org/https://doi.org/10.1097/AOG.0000000000003500
- Kirsch, I., & Moncrieff, J. (2007). Clinical trials and the response rate illusion. Contemporary Clinical Trials, 28(4), 348–351. https://doi.org/https://doi.org/10.1016/j.cct.2006.10.012
- Kraemer, H. C., & Robinson, T. N. (2005). Are certain multicenter randomized clinical trial structures misleading clinical and policy decisions? Contemporary Clinical Trials, 26(5), 518–529. https://doi.org/https://doi.org/10.1016/j.cct.2005.05.002
- Lane, C. (2008). Shyness: How normal behavior became a sickness. Yale University Press.
- Laumann, E. O., Paik, A., & Rosen, R. C. (1999). Sexual dysfunction in the United States: Prevalence and predictors. JAMA, 281(6), 537–544. https://doi.org/https://doi.org/10.1001/jama.281.6.537
- Le Noury, J., Nardo, J. M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2015). Restoring study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351(8025), h4320. https://doi.org/https://doi.org/10.1136/bmj.h4320
- Logdberg, L. (2011). Being the ghost in the machine: A medical ghostwriter’s personal view. PLOS Medicine, 8(8), e1001071. https://doi.org/https://doi.org/10.1371/journal.pmed.1001071
- MacCallum, R. C., Zhang, S., Preacher, K. J., & Rucker, D. D. (2002). On the practice of dichotomization of quantitative variables. Psychological Methods, 7(1), 19. https://doi.org/https://doi.org/10.1037/1082-989X.7.1.19
- Masouleh, S. K., Eickhoff, S. B., Hoffstaedter, F., Genon, S., & Initiative, A. D. N. (2019). Empirical examination of the replicability of associations between brain structure and psychological variables. Elife, 8, e43464. https://doi.org/https://doi.org/10.7554/eLife.43464
- Matheson, A. (2016a). Ghostwriting: The importance of definition and its place in contemporary drug marketing. BMJ, 354(8071). https://doi.org/https://doi.org/10.1136/bmj.i4578
- Matheson, A. (2016b). The disposable author: How pharmaceutical marketing is embraced within medicine’s scholarly literature. Hastings Center Report, 46(4), 31–37. https://doi.org/https://doi.org/10.1002/hast.576
- Mathieu, S., Boutron, I., Moher, D., Altman, D. G., & Ravaud, P. (2009). Comparison of registered and published primary outcomes in randomized controlled trials. Journal of the American Medical Association, 302(9), 977–984. https://doi.org/https://doi.org/10.1001/jama.2009.1242
- Mathieu, S., Chan, A.-W., Ravaud, P., & Smalheiser, N. R. (2013). Use of trial register information during the peer review process. PLoS ONE, 8(4), e59910. https://doi.org/https://doi.org/10.1371/journal.pone.0059910
- Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J. K., Dickersin, K., Cowley, T., Doshi, P., Ehmsen, J., Gresham, G., Guo, N., Haythornthwaite, J., Heyward, J., Pham, D., Payne, J., Rosman, L., Stuart, E., Suarez-Cuervo, C., Tolbert, E., Vedula, S., & Bertizzolo, L. (2019a). Harms are assessed inconsistently and reported inadequately Part 1: Systematic adverse events. Journal of Clinical Epidemiology, 113(3), 20–27. https://doi.org/https://doi.org/10.1016/j.jclinepi.2019.04.022
- Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J. K., Dickersin, K., Cowley, T., Doshi, P., Ehmsen, J., Gresham, G., Guo, N., Haythornthwaite, J., Heyward, J., Pham, D., Payne, J., Rosman, L., Stuart, E., Suarez-Cuervo, C., Tolbert, E., Vedula, S., & Bertizzolo, L. (2019b). Harms are assessed inconsistently and reported inadequately Part 2: Nonsystematic adverse events. Journal of Clinical Epidemiology, 113(3), 11–19. https://doi.org/https://doi.org/10.1016/j.jclinepi.2019.04.020
- McHenry, L. B., & Amsterdam, J. D. (2019). The paroxetine 352 bipolar study revisited: Deconstruction of corporate and academic misconduct. Journal of Scientific Practice and Integrity, 1(1). https://doi.org/https://doi.org/10.35122/jospi.2019.958452
- McHenry, L. B., & Jureidini, J. N. (2008). Industry-sponsored ghostwriting in clinical trial reporting: A case study. Accountability In Research, 15(3), 152–167. https://doi.org/https://doi.org/10.1080/08989620802194384
- Meixel, A., Yanchar, E., & Fugh-Berman, A. (2015). Hypoactive sexual desire disorder: Inventing a disease to sell low libido. Journal of Medical Ethics, 41(10), 859–862. https://doi.org/https://doi.org/10.1136/medethics-2014-102596
- Merriam-Webster. (2020, January 20). Definition of ghostwriting. Merriam-Webster. https://www.merriam-webster.com/dictionary/ghostwriting
- Mills, J. L. (1993). Data torturing. The New England Journal of Medicine, 329(16), 1196–1199. https://doi.org/https://doi.org/10.1056/NEJM199310143291613
- Mitchell, K. R., Jones, K. G., Wellings, K., Johnson, A. M., Graham, C. A., Datta, J., Bancroft, J., Sonnenberg, P., Macdowall, W., Field, N., Mercer, C. H., & Copas, A. J. (2016). Estimating the prevalence of sexual function problems: The impact of morbidity criteria. Journal of Sex Research, 53(8), 955–967. https://doi.org/https://doi.org/10.1080/00224499.2015.1089214
- Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010). CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ, 340(mar23 1), c869. https://doi.org/https://doi.org/10.1136/bmj.c869
- Moynihan, R. (2003). The making of a disease: Female sexual dysfunction. BMJ, 326(7379), 45–47. https://doi.org/https://doi.org/10.1136/bmj.326.7379.45
- Neijenhuijs, K. I., Hooghiemstra, N., Holtmaat, K., Aaronson, N. K., Groenvold, M., Holzner, B., Terwee, C. B., Cuijpers, P., & Verdonck-de Leeuw, I. M. (2019). The Female Sexual Function Index (FSFI)—A systematic review of measurement properties. The Journal of Sexual Medicine, 16(5), 640–660. https://doi.org/https://doi.org/10.1016/j.jsxm.2019.03.001
- Obstetrics & Gynecology. (2019). RE: Manuscript number ONG-19-803. Lippincott Williams & Wilkins. Retrieved from Your Submission ONG-19-80e website: https://cdn-links.lww.com/permalink/aog/b/aog_134_5_2019_09_12_kingsberg_19-803_sdc2.pdf
- Obstetrics & Gynecology. (2020). Instructions for authors: Obstetrics & gynecology. Lippincott Williams & Wilkins. https://journals.lww.com/greenjournal/Pages/instructionsforauthors.aspx
- Open Science Collaboration. (2015). Estimating the reproducibility of psychological science. Science, 349(6251), 6251. https://doi.org/https://doi.org/10.1126/science.aac4716
- Palatin Technologies. (2014). A placebo-controlled, randomized, parallel group, dose-finding trial to evaluate the efficacy and safety of subcutaneously administered bremelanotide in premenopausal women with FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder) (Clinical Trial Registration No. NCT01382719). clinicaltrials.gov. Retrieved from clinicaltrials.gov website: https://clinicaltrials.gov/ct2/show/NCT01382719
- Paris, J. (2009). The bipolar spectrum: A critical perspective. Harvard Review of Psychiatry, 17(3), 206–213. https://doi.org/https://doi.org/10.1080/10673220902979888
- Paris, J. (2015). Overdiagnosis in psychiatry: How modern psychiatry lost its way while creating a diagnosis for almost all of life’s misfortunes. Oxford University Press.
- Phase Five Publications. (n.d.). This is grey. Phase Five Publications. https://www.phase-five.com/sites/phasefivecom/files/pdfs/Doing_It_Right.pdf
- Phase Five Communications. (2020). Phase five communications. Phase Five Communications. Retrieved from Phase Five | Home website: https://www.phase-five.com/
- Revicki, D. A., Clayton, A. H., Stouch, B. C., Portman, D. J., Kingsberg, S. A., DeRogatis, L. R., & Jordan, R. (2018, February 20). Developing clinically meaningful responder thresholds for primary endpoints for clinical trials in premenopausal women with hypoactive sexual desire disorder. Presented at the International Society for CNS Trials and Methodology, Washington, DC.
- Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015). Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: A report of 2 meta-analyses. JAMA Psychiatry, 72(5), 500–510. https://doi.org/https://doi.org/10.1001/jamapsychiatry.2015.15
- Rosen, R. (2000). The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy, 26(2), 191–208. https://doi.org/https://doi.org/10.1080/009262300278597
- Ross, J. S., Hill, K. P., Egilman, D. S., & Krumholz, H. M. (2008). Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA, 299(15), 1800–1812. https://doi.org/https://doi.org/10.1001/jama.299.15.1800
- Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., Krumholz, H. M., & Sim, I. (2009). Trial publication after registration in ClinicalTrials.Gov: A cross-sectional analysis. PLoS Medicine, 6(9), e1000144. https://doi.org/https://doi.org/10.1371/journal.pmed.1000144
- Sakaluk, J. K., & Graham, C. A. (2018). Promoting transparent reporting of conflicts of interests and statistical analyses at The Journal of Sex Research. Journal of Sex Research, 55(1), 1–6. https://doi.org/https://doi.org/10.1080/00224499.2017.1395387
- Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. PLoS Medicine, 7(3), e1000251. https://doi.org/https://doi.org/10.1371/journal.pmed.1000251
- Schwarz, A. (2016). ADHD nation. Scribner.
- Segal, J. Z. (2015). The rhetoric of female sexual dysfunction: Faux feminism and the FDA. CMAJ, 187(12), 915–916. https://doi.org/https://doi.org/10.1503/cmaj.150363
- Segal, J. Z. (2018). Sex, drugs, and rhetoric: The case of flibanserin for ‘female sexual dysfunction.’. Social Studies of Science, 48(4), 459–482. https://doi.org/https://doi.org/10.1177/0306312718778802
- Simmons, J. P., Nelson, L. D., & Simonsohn, U. (2011). False-positive psychology: Undisclosed flexibility in data collection and analysis allows presenting anything as significant. Psychological Science, 22(11), 1359–1366. https://doi.org/https://doi.org/10.1177/0956797611417632
- Sismondo, S. (2007). Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine, 4(9), e286–e286. https://doi.org/https://doi.org/10.1371/journal.pmed.0040286
- Sismondo, S. (2018). Ghost-managed medicine: Big pharma’s invisible hands. Mattering Press.
- Sismondo, S., & Nicholson, S. H. (2009). Publication planning 101. Journal of Pharmacy & Pharmaceutical Sciences, 12(3), 273–279. https://doi.org/https://doi.org/10.18433/J3WW2R
- Spielmans, G. I. (2009). The promotion of olanzapine in primary care: An examination of internal industry documents. Social Science & Medicine, 69(1), 14–20. https://doi.org/https://doi.org/10.1016/j.socscimed.2009.05.001
- Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013). Adjunctive atypical antipsychotics for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Medicine, 10(3), e1001403. https://doi.org/https://doi.org/10.1371/journal.pmed.1001403
- Spielmans, G. I., & Parry, P. I. (2010). From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. Journal of Bioethical Inquiry, 7(1), 13–29. https://doi.org/https://doi.org/10.1007/s11673-010-9208-8
- Szucs, D., Ioannidis, J. P. A., & Wagenmakers, E.-J. (2017). Empirical assessment of published effect sizes and power in the recent cognitive neuroscience and psychology literature. PLOS Biology, 15(3), e2000797. https://doi.org/https://doi.org/10.1371/journal.pbio.2000797
- Tavernise, S., & Pollack, A. (2015, June 13). Aid to women, or bottom lne? Advocates split on libido pill. The New York Times. https://www.nytimes.com/2015/06/14/us/aid-to-women-or-bottom-line-advocates-split-on-libido-pill.html
- Tiefer, L. (2006). Female sexual dysfunction: A case study of disease mongering and activist resistance. PLOS Medicine, 3(4), e178. https://doi.org/https://doi.org/10.1371/journal.pmed.0030178
- Turner, E. H. (2013). Publication bias, with a focus on psychiatry: Causes and solutions. CNS Drugs, 27(6), 457–468. https://doi.org/https://doi.org/10.1007/s40263-013-0067-9
- Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3), 252–260. https://doi.org/https://doi.org/10.1056/NEJMsa065779
- United States Food and Drug Administration. (2019). United States Food and Drug Administration. Retrieved from New Drug Application Multi-Disciplinary Review and Evaluation Standard 210557: Vyleesi/Bremelanotide website: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000TOC.cfm